Glioblastoma remains an almost universally fatal cancer with few recent therapeutic advances. The gene encoding EGFR is the most frequently amplified gene in glioblastoma, with roughly 40% of primary glioblastomas showing EGFR amplification.¹ Of these EGFR-amplified glioblastomas, 20–50% are characterised by a truncated gene resulting in the expression of mutated EGFRvIII, which is constitutively active. Activation of the EGFR pathway promotes several downstream pathways with oncogenic potential such as cellular proliferation and invasiveness.

中文翻译：

---

ACT IV：rindopepimut的最终决定？

胶质母细胞瘤仍然是几乎普遍致命的癌症，最近的治疗进展很少。编码EGFR的基因是胶质母细胞瘤中最常见的扩增基因，约40％的原发性胶质母细胞瘤显示EGFR扩增。¹在这些EGFR扩增的胶质母细胞瘤中，有20％至50％的特征是基因被截断，导致突变的EGFRvIII的表达具有活性。EGFR途径的激活促进了几种具有致癌潜力的下游途径，例如细胞增殖和侵袭性。